#MelanomaResearchUpdate -- Cancer cells can evade the immune system and avoid being destroyed. Current #immunotherapy works by helping immune cells attack tumors, but not all patients respond and patients who respond could develop resistance VSports app下载. In a recent Journal for ImmunoTherapy of Cancer article, Dr. Keiran Smalley, MRF’s Scientific Research Officer and Director of Skin Cancer Research Center at Moffitt Cancer Center, demonstrates promising advances for treatment-resistant melanoma by adding a third drug, anti-TIM-3, to the combination therapy (anti-PD1 + anti-LAG3) in pre-clinical models. “Our findings offer a new approach to treating melanoma in patients who currently have few options,” says Dr. Smalley. “We’re excited about the potential to bring this strategy to clinical trials and ultimately to patients. ” Read more: https://lnkd. in/e8WtiQMf .
New melanoma treatment strategy for resistant cases: anti-TIM-3 added to combo therapy
此标题由 AI 根据以下动态总结生成。
最相关的动态
-
Up next in our Cancer Research Communications Article Showcase series is a featured selection from Justin Balko, Senior Editor of Immuno-oncology: “Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma” https://brnw. ch/21wWhYC Immunotherapy has revolutionized cancer treatment. However, many patients' tumors still respond suboptimally to immunotherapeutic modalities, necessitating biomarker discovery and rational combination therapies. This study addresses the latter, showing that targeting EGFR and MET with the bispecific antibody amivantamab ameliorates the glycolytic and immunosuppressive response to pembrolizumab in lung and head and neck squamous cell carcinomas. Read the latest articles from this section: https://brnw VSports手机版. ch/21wWhYD.
-
-
Moores Member Scott Lippman, MD has published a game-changing study identifying why some patients don't respond to immune checkpoint therapy (ICT) and what we can do about it. 💡 His results offer new insight into this fundamental challenge in oncology and have sparked the development of a new cancer vaccine that could optimize the effectiveness of ICT. Dive into the research shaping the next frontier in cancer care here: https://bit V体育ios版. ly/46gFKkK #Immunotherapy #CancerVaccine #ICT #OncologyResearch #MooresCancerCenter.
-
Pancreatic cancer is among the most treatment-resistant cancers, with only a 13% five-year survival rate V体育平台登录. Researchers at IU Simon Comprehensive Cancer Center and Indiana University School of Medicine have identified a dual-target strategy that weakens the disease's defenses. By blocking two proteins, Ref-1 and PRDX1, researchers saw tumors shrink and fewer cancer cells survive. Notably, this approach disrupted both tumor cells and their surrounding microenvironment, offering a broader path forward in tackling pancreatic cancer and potentially other aggressive cancers. This work underscores the importance of collaborative cancer research and the pursuit of new therapeutic approaches. Learn more: https://ow. ly/aPmq50WYSy9. #ResearchCuresCancer.
-
-
ICYMI: Last week we announced a collaboration with a leading breast cancer team from Yale Cancer Center for the CATE clinical trial, a novel ctDNA-guided study aimed at improving outcomes in patients with breast cancer. The prospective, multi-center trial, sponsored by the Translational Breast Cancer Research Consortium (TBCRC) and led by Dr V体育官网入口. Mariya Rozenblit and Dr. Maryam Lustberg at Yale Cancer Center, will investigate whether earlier, ultrasensitive ctDNA-guided intervention can prevent metastatic relapse and improve outcomes for patients with HR+/HER2- breast cancer. HR+/HER2- breast cancer, which accounts for over 70% of all cases, poses a significant challenge due to the risk of late recurrence. The CATE trial utilizes the NeXT Personal® test to identify the earliest molecular signs of recurrence, ahead of standard imaging. Patients who test positive will be preemptively treated with elacestrant, a next-generation therapy, with the goal of eliminating cancer before it becomes metastatic. Learn more from the press release: https://bit. ly/4grSkT0 See what’s being said in the news about this pivotal trial: https://bit. ly/4pwujym #PrecisionOncology #ctDNA #BreastCancer #ClinicalTrials #PrecisionMedicine #NGS.
-
1. Researchers at UC Irv have developed a new class of immunotherapeutics that can kill various cancer types without harming healthy tissue 2.study focuses on targeting cancer-associated glycans using glycan-dependent T cell recruiter (GlyTR) compounds, which penetrate tumor cell defenses &trigger their death 3. GlyTR1 &GlyTR2 have shown safety &effectiveness across multiple cancer models, including breast, colon, lung, ovarian, pancreatic,&prostate cancers 4.research is considered a significant advancement in cancer treatment, potentially revolutionizing how cancer patients are treated 5.GlyTR tech addresses key challenges in current immunotherapies: differentiating btw cancer &normal cells &overcoming cancer's immune suppression 6. The researchers took an unconventional approach by targeting glycan coatings on cancer cells, which are abundant but often overlooked by traditional research 7. GlyTR compounds attach to high-glycan-density cancer cells, marking them for destruction by the immune system while sparing healthy cells 8.next phase includes developing clinical-grade GlyTR1 &commencing human trials to assess safety &effectiveness, expected to start within two years 9. The innovative treatment approach aims to meet urgent needs of patients with refractory/metastatic cancers
-
PhD Immunotherapy Expert | R&D | TCEs | bi-specific, tri-specific abs | CAR-T, TCR-T & MSCs | Assay Development | Analytical Development | Process Development | Immuno-oncology| Extracellular vesicles
A recent study from MD Anderson Cancer Center illustrates how oncogene targeting and T-cell based immunotherapy can converge to tackle pancreatic cancer, a tumor type typically poorly accessible to immune cells. The authors show that exosomes delivering siRNA against mutant KRAS silence oncogenic signaling and reprogram the tumor microenvironment. Remarkably, this also restores CD8 T-cell infiltration and synergizes with CTLA-4 blockade. The next generation of therapies may not choose between oncogene targeting and immune modulation but use both in a powerful combination converting cold, immune excluded tumors into immune responsive ones.
-
Overcoming Resistance to CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer In a recent review published in Cancer Treatment Reviews (2025), Federica Giugliano and colleagues provide an insightful overview of the mechanisms and strategies to overcome resistance to CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer. While the combination of CDK4/6 inhibitors with endocrine therapy has transformed treatment outcomes, resistance both intrinsic and acquired remains a major clinical challenge. The study highlights key pathways driving resistance and explores innovative therapeutic combinations, including the integration of targeted agents such as PI3K, AKT, and mTOR inhibitors. This review emphasizes the importance of translational research and biomarker-driven approaches to refine treatment sequencing and develop next-generation strategies capable of restoring endocrine sensitivity in resistant HR-positive disease. We thank Federica Giugliano and her co-authors for their significant contribution to advancing our understanding of resistance mechanisms and shaping the future of personalized breast cancer therapy. Read more: https://lnkd.in/dx6dMiqT #BreastCancerResearch #OncologyFrontier #CDK46Inhibitors #EndocrineTherapy #TranslationalResearch #PrecisionOncology #CancerTreatment #HormoneReceptorPositive
-
-
Founder and CEO, Striver Health Innovations LLC I Adjunct Professor Stanford University | Visiting Professor Riga Stradins University | Board Director | Former Health System CEO & University Executive
Important new research findings which might influence staging criteria for cancer and reinforces importance of treating tobacco use disorder at any age and integrating into cancer treatment and care.
Groundbreaking research led by Graham Warren, M.D., Ph.D., of the UK Markey Cancer Center and international collaborators shows that smoking status at the time of lung cancer diagnosis has a profound impact on survival, so significant that it should be considered when staging lung cancer. The study, published in the Journal of Thoracic Oncology, analyzed nearly 49,000 patients across 25 countries. Results revealed that smoking history may be as important, or more important, than some traditional staging factors in determining prognosis. These findings could help reshape global lung cancer staging guidelines, improve patient outcomes, and reinforce the urgent need to integrate smoking cessation into cancer care. Read more about how Markey researchers are redefining cancer care ➡️ https://lnkd.in/eMuACDgk
-
-
HER3-DXd is emerging as a potential new option for patients with HR+/HER2− breast cancer, a population that continues to face limited treatment choices after progression on endocrine therapy. In the ICARUS-BREAST01 trial, HER3-DXd demonstrated a 53.5% response rate. But how should we interpret these results compared with T-DXd in HER2-low or HER2-zero disease, and what does this mean for real-world practice? In this interview, Dr Barbara Pistilli, head of the Breast Cancer Unit at Gustave Roussy Éducation Cancer Center, walks through the trial data, why study design matters, and how emerging biomarkers such as ESR1 mutations, TP53 status, and tumor architecture could help identify patients most likely to benefit. She also touches on immune pathway activation, the potential for ADC–immunotherapy combinations, and the unanswered questions heading into phase III. Watch the full conversation here: 👉 https://lnkd.in/gPqX-sU7 Read the full study in Nature Portfolio Medicine: https://lnkd.in/gzHmQ8ek Paolo Tarantino Sarah Sammons MD Maria Fernanda Mosele Noémie Corcos Livia Pierotti Yoann Pradat Loïc Le Bescond
-
This Blood Cancer Awareness Month, we’re spotlighting multiple myeloma, a complex blood cancer that develops from abnormal plasma cells in the bone marrow. Although the cancer is currently incurable, we’re proud to now offer CARVYKTI®, a cutting-edge CAR-T cell therapy that can provide long-term control of the disease. CAR-T therapy works by collecting a patient’s T cells, reprogramming them to recognise specific proteins on myeloma cells, and then reintroducing them to target and destroy the cancer. This pioneering treatment is available at our Duchess of Devonshire Wing Cancer Centre, supported by our dedicated haematology specialists. 🔗 Learn more: https://bit.ly/47VYTLy #BloodCancerAwarenessMonth #MultipleMyeloma #CARVYKTI #Immunotherapy #TheLondonClinic
-
